Paper - WANFANG MED ONLINE

You Position: Home > Paper

Conversion therapy for primary liver cancer:Indications and selective strategies

( views:0, downloads:0 )

Author:: No author available

Journal Title:: World Chinese Journal of Digestology

Issue:: 10

DOI:: 10.11569/wcjd.v29.i10.501

Key Word:: 原发性肝癌;转化治疗;指征;策略

Abstract：原发性肝癌发病隐匿,早期无特异性症状,多数患者确诊时已属中晚期,符合根治性切除术的患者20％-40％.目前外科切除仍是原发性肝癌主要根治性治疗手段,但由于肝功能失代偿、肿瘤体积过大、剩余肝体积过小、肝内多发转移、癌栓侵及大血管或胆管、远处转移等因素限制手术切除或肝移植.近年来,随着原发性肝癌发生、发展机制研究的不断深入,外科技术和器械发展,以及新的分子靶向药物、免疫治疗药物的研制,使得一部分无法手术切除或肝移植的原发性肝癌患者经过转化治疗,改善肝功能、缩小肿瘤体积、使脉管癌栓缩小或消失、促进剩余肝脏体积代偿性增大,最终得以手术切除或肝移植,极大提高了原发性肝癌治疗效果和患者生存期.

Reference

[1]Wan Yee Lau,Eric CH Lai,Stephanie HY Lau.Associating liver partition and portal vein ligation for staged hepatectomy: the current role and development[J].2017,(1).
[2]刘臻玉,武丹,区锦玲,等.术后TACE对肝癌微血管侵犯治疗效果评估[J].2017,(5).
[3]中国抗癌协会.肝门部胆管癌规范化诊治专家共识（2015）[J].2015,(8).
[4]赖俊雄,刘晓欣,刘允怡.原发性肝癌降期手术新进展[J].2015,(1).
[5]Masami Minagawa,Masatoshi Makuuchi.Treatment of hepatocellular carcinoma accompanied by portal vein tumor thrombus[J].2006,(47).
[6].The current role of neoadjuvant/adjuvant/chemoprevention therapy in partial hepatectomy for hepatocellular carcinoma:a systematic review[J].2009,(2).
[7]Bao-Gang Peng,Li-Jian Liang,Shao-Qiang Li,etc.Surgical treatment of hepatocellular carcinoma with bile duct tumor thrombi[J].2005,(25).
[8]中国医师协会器官移植医师分会,中华医学会器官移植学分会.中国肝癌肝移植临床实践指南（2018版）[J].2019,(2).
[9]李川江,周杰.肝细胞肝癌经肝动脉化疗栓塞联合索拉非尼降期后二期切除的初步报告[J].2017,(4).
[10]王浩,陈光,高海军,等.载药微球介入栓塞治疗在肝癌肝移植术前降期治疗中的应用[J].2019,(5).
[11]王浩,陈光,高海军,等.载药微球化疗栓塞在肝癌患者肝移植等待期间应用的疗效分析[J].2019,(4).
[12]黄琨博,范文哲,张应强,等.TACE 联合冷冻消融治疗不可切除性大肝癌的临床分析[J].2016,(37).
[13].Gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma: A large multicenter AGEO study[J].2013,58(1).
[14]Baker T,Salem R,Omary R,etc.A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization.[J].2009,9(8).
[15]Shukui, Qin,Yuxian, Bai,Ho Yeong, Lim,etc.Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.[J].2013,31.
[16]L, Barbier,F, Muscari,S, Le Guellec,etc.Liver resection after downstaging hepatocellular carcinoma with sorafenib.[J].2011,2011.
[17].ALPPS offers a better chance of complete resection in patients with primarily unresectable liver tumors compared with conventional-staged hepatectomies: Results of a multicenter analysis[J].2014,38(6).
[18]Adeel S, Khan,Sandra, Garcia-Aroz,Mohammad A, Ansari,etc.Assessment and optimization of liver volume before major hepatic resection: Current guidelines and a narrative review.[J].2018,(Spec ).
[19]Zhipeng, Sun,Wei, Tang,Yoshihiro, Sakamoto,etc.A systematic review and meta-analysis of feasibility, safety and efficacy of associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) versus two-stage hepatectomy (TSH).[J].2015,9(5).
[20]Sang Min, Yoon,Baek-Yeol, Ryoo,So Jung, Lee,etc.Efficacy and Safety of Transarterial Chemoembolization Plus External Beam Radiotherapy vs Sorafenib in Hepatocellular Carcinoma With Macroscopic Vascular Invasion: A Randomized Clinical Trial.[J].2018,(Spec ).
[21]Eke,Ransome,Li,Tong,Jairo,Espinosa,etc.Trends in surgery and disparities in receipt of surgery for intrahepatic cholangiocarcinoma in the US: 2005-2014.[J].2019,10(2).
[22]张秋明,钟鉴宏,游雪梅,等.核苷类似物联合TACE治疗HBV相关性肝细胞癌的预后分析[J].2016,(9).
[23]Breno Boueri,Affonso,Francisco Leonardo,Galastri,Joaquim Mauricio,da Motta Leal Filho,etc.Long-term outcomes of hepatocellular carcinoma that underwent chemoembolization for bridging or downstaging.[J].2019,25(37).
[24]Yoshimoto, Toshiaki,Imura, Satoru,Morine, Yuji,etc.The Outcome of Sorafenib Therapy on Unresectable Hepatocellular Carcinoma: Experience of Conversion and Salvage Hepatectomy[J].2018,38(1).
[25]Salem, Riad,Gordon, Andrew C.,Mouli, Samdeep,etc.Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma[J].2016,151(6).
[26]Hirose R,Vagefi PA.Downstaging of hepatocellular carcinoma prior to liver transplant: is there a role for adjuvant sorafenib in locoregional therapy?[J].2010,41(4).
[27]Michinori Hamaoka,Tsuyoshi Kobayashi,Shintaro Kuroda,etc.Hepatectomy after down-staging of hepatocellular carcinoma with portal vein tumor thrombus using chemoradiotherapy: A retrospective cohort study[J].2017,44.
[28]Bruix J,Sherman M.Management of hepatocellular carcinoma: an update.[J].2011,53(3).
[29]長谷川高士.災害を通じて考えること[J].2004,0(219).
[30]Josep M, Llovet,Sergio, Ricci,Vincenzo, Mazzaferro,etc.Sorafenib in advanced hepatocellular carcinoma.[J].2008,359.
[31]Gall, Tamara M. H.,Sodergren, Mikael H.,Frampton, Adam E.,etc.Radio-frequency-assisted Liver Partition With Portal Vein Ligation (RALPP) for Liver Regeneration[J].2015,261(2).
[32]Salvatore, Gruttadauria,Fabio, Vasta,Minervini, Marta Ida,etc.Significance of the Effective Remnant Liver Volume in Major Hepatectomies[J].2005,71(3).
[33]Tullio, Piardi,Ricardo, Memeo,Yohann, Renard,etc.Management of large hepatocellular carcinoma by sequential transarterial chemoembolization and portal vein embolization: a systematic review of the literature.[J].2016.
[34]Lei, Huang,Guang-Ming, Li,Ji-Ye, Zhu,etc.Efficacy of sorafenib after liver transplantation in patients with primary hepatic carcinoma exceeding the Milan criteria: a preliminary study.[J].2012,5.
[35]Huang, Dong Sheng,Hong, De Fei,Peng, Shu You,etc.Percutaneous Microwave Ablation Liver Partition and Portal Vein Embolization for Rapid Liver Regeneration A Minimally Invasive First Step of ALPPS for Hepatocellular Carcinoma[J].2016,264(1).
[36]J, Fan,Z Y, Tang,Y Q, Yu,etc.Improved survival with resection after transcatheter arterial chemoembolization (TACE) for unresectable hepatocellular carcinoma.[J].1998,15(6).
[37]Buac, Suzana,Schadde, Erik,Schnitzbauer, Andreas A.,etc.The many faces of ALPPS: surgical indications and techniques among surgeons collaborating in the international registry[J].2016,18(5).
[38]Yongjie,Shui,Wei,Yu,Xiaoqiu,Ren,etc.Stereotactic body radiotherapy based treatment for hepatocellular carcinoma with extensive portal vein tumor thrombosis.[J].2018,13(1).
[39]Bray Freddie,Ferlay Jacques,Torre Lindsey A.,etc.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].2018,68(6).
[40]Beom-Hui,Lee,Dong-Shik,Lee,Chan Woo,Cho,etc.Role and limitation of neoadjuvant hepatic arterial infusion chemotherapy in advanced hepatocelluar carcinoma patients with Child-Pugh class A.[J].2019,17(1).
[41]Vicente, E.,Quijano, Y.,Ielpo, B.,etc.First ALPPS procedure using a total robotic approach[J].2016,25(4).
[42]Shu-You Peng,Xu-An Wang,Cong-Yun Huang,etc.Evolution of associating liver partition and portal vein ligation for staged hepatectomy: Simpler, safer and equally effective methods[J].2017,(23).
[43]Fujiki M,Aucejo F,Kim R.General overview of neo-adjuvant therapy for hepatocellular carcinoma before liver transplantation: necessity or option?[J].2011,31(8).
[44]Zhao-Chong Zeng,Zhao-You Tang,Bing-Hui Yang,etc.Comparison between radioimmunotherapy and external beam radiation therapy for patients with hepatocellular carcinoma[J].2002,29(12).
[45]Rayar, M.,Sulpice, L.,Edeline, J.,etc.Intra-arterial Yttrium-90 Radioembolization Combined with Systemic Chemotherapy is a Promising Method for Downstaging Unresectable Huge Intrahepatic Cholangiocarcinoma to Surgical Treatment[J].2015,22(9).
[46]Maryvonne Daveau,Michel Scotte,Arnaud François,etc.Hepatocyte growth factor, transforming growth factor <img src="http://onlinelibrarystatic.wiley.com/undisplayable_characters/0003b1.gif" alt="[alpha]"/>, and their receptors as combined markers of prognosis in hepatocellular carcinoma[J].2003,36(3).
[47]S. Ogata,J. Belghiti,O. Farges,etc.Sequential arterial and portal vein embolizations before right hepatectomy in patients with cirrhosis and hepatocellular carcinoma[J].2006,93(9).
[48]Aloia, Thomas A..Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy Portal Vein Embolization Should Remain the Gold Standard[J].2015,150(10).
[49]Tamandl D,Freimann Pircher S,Roka R,etc.Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study.[J].2010,11(12).
[50]Piron, Lauranne,Deshayes, Emmanuel,Escal, Laure,etc.Portal vein embolization: Present and future[J].2017,104(5).
[51]Hyung Soon Lee,Gi Hong Choi,Jin Sub Choi,etc.Surgical resection after down-staging of locally advanced hepatocellular carcinoma by localized concurrent chemoradiotherapy.[J].2014,21(11).
[52]Tatsuaki Sumiyoshi,Yasuo Shima,Takehiro Okabayashi,etc.Chemoradiotherapy for Initially Unresectable Locally Advanced Cholangiocarcinoma[J].2018,42(9).
[53]Nadalin,S.,Capobianco,I.,Li,J.,etc.Indications and limits for associating liver partition and portal vein ligation for staged hepatectomy (ALPPS)lessons learned from 15 cases at a single centre[J].2014,52(1).
[54]He, MinKe,Li, QiJiong,Zou, RuHai,etc.Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion A Randomized Clinical Trial[J].2019,5(7).
[55]O'Donnell, Jake S.,Hoefsmit, Esmee P.,Smyth, Mark J.,etc.The Promise of Neoadjuvant Immunotherapy and Surgery for Cancer Treatment[J].2019,25(19).
[56]Zhang,R.,Xu,L.-B.,Zeng,H.,etc.Elevated expression of Bmi1 in hepatocellular carcinoma with bile duct tumor thrombi[J].2013,60(128).
[57]Allard, Marc-Antoine,Sebagh, Mylene,Ruiz, Aldrick,etc.Does pathological response after transarterial chemoembolization for hepatocellular carcinoma in cirrhotic patients with cirrhosis predict outcome after liver resection or transplantation?[J].2015,63(1).
[58]Hwang, Shin,Ha, Tae-Yong,Ko, Gi-Young,etc.Preoperative Sequential Portal and Hepatic Vein Embolization in Patients with Hepatobiliary Malignancy[J].2015,39(12).
[59].Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial[J].2020,21(4).
[60]Huang, Yun,Zhang, Zeyu,Zhou, Yufan,etc.Should we apply sorafenib in hepatocellular carcinoma patients with microvascular invasion after curative hepatectomy?[J].2019,12.
[61]Vennarecci,G.,Laurenzi,A.,LeviSandri,G.B.,etc.The ALPPS procedure for hepatocellular carcinoma[J].2014,40(8).
[62]Labgaa, Ismail,Tabrizian, Parissa,Titano, Joseph,etc.Feasibility and safety of liver transplantation or resection after transarterial radioembolization with Yttrium-90 for unresectable hepatocellular carcinoma[J].2019,21(11).
[63]Mouli,S.,Memon,K.,Baker,T.,etc.Yttrium-90 radioembolization for intrahepatic cholangiocarcinoma: Safety, response, and survival analysis[J].2013,24(8).
[64]Oldhafer, Karl J.,Stavrou, Gregor A.,van Gulik, Thomas M..ALPPS-Where Do We Stand, Where Do We Go? Eight Recommendations From the First International Expert Meeting[J].2016,263(5).
[65]Le Roy B.,Gelli M.,Pittau G.,etc.Neoadjuvant chemotherapy for initially unresectable intrahepatic cholangiocarcinoma[J].2018,105(7).
[66]Marco, Massani,Cristina, Nistri,Cesare, Ruffolo,etc.Intrahepatic chemotherapy for unresectable cholangiocarcinoma: review of literature and personal experience.[J].2015,67.
[67]Schnitzbauer,A.A.,Lang,S.A.,Goessmann,H.,etc.Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings[J].2012,255(3).
[68]Zhang, Xiu-Ping,Chai, Zong-Tao,Gao, Yu-Zhen,etc.Postoperative adjuvant sorafenib improves survival outcomes in hepatocellular carcinoma patients with microvascular invasion after R0 liver resection: a propensity score matching analysis[J].2019,21(12).
[69]Sun,Y.,Ge,R.-L.,Yuan,L.,etc.Survival benefit of surgical treatment for hepatocellular carcinoma with inferior vena cava/right atrium tumor thrombus: Results of a retrospective cohort study[J].2013,20(3).
[70]Figer A,Schwartz L,Schwartz B,etc.Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.[J].2006,24(26).
[71]Robles,R.,Parrilla,P.,L?pez-Conesa,A.,etc.Tourniquet modification of the associating liver partition and portal ligation for staged hepatectomy procedure[J].2014,101(9).
[72]Sofía, Sala,Victoria, Ardiles,Marina, Ulla,etc.Our initial experience with ALPPS technique: encouraging results.[J].2012,64(3).
[73]Josep M, Llovet,Jessica, Zucman-Rossi,Eli, Pikarsky,etc.Hepatocellular carcinoma.[J].2016.
[74]Zong-ming, Zhang,Eric C H, Lai,Chong, Zhang,etc.The strategies for treating primary hepatocellular carcinoma with?portal vein tumor thrombus.[J].2015,20.
[75]Dawkins, Joshua,Webster, Rachel M..The hepatocellular carcinoma market[J].2019,18(1).
[76]Gang, Huang,Peng-Peng, Li,Wan Yee, Lau,etc.Antiviral Therapy Reduces Hepatocellular Carcinoma Recurrence in Patients With Low HBV-DNA Levels: A Randomized Controlled Trial.[J].2018,(Spec ).
[77]Wang,S.-N.,Chuang,S.-C.,Lee,K.-T..Efficacy of sorafenib as adjuvant therapy to prevent early recurrence of hepatocellular carcinoma after curative surgery: A pilot study[J].2014,44(5).
[78]Adel Abulkhir,Paolo Limongelli,Andrew J. Healey,etc.Preoperative Portal Vein Embolization for Major Liver Resection[J].2009,247(1).
[79]A. A. Titov,A. I. Merentsov,A. E. Kar'kin,etc.A. Titov, A.I. Merentsov, A.E. Kar'kin, A.N. Titov, VV Fedorenko, 2009, published in Fizika Tverdogo Tela, 2009, Vol. 51, No. 2, pp. 217-220.Structure and Properties of the Intercalation Compound Cu_xTiSe_2[J].2009,51(2).
[80]Paul, Sonali,Dickstein, Aaron,Saxena, Akriti,etc.Role of Surface Antibody in Hepatitis B Reactivation in Patients With Resolved Infection and Hematologic Malignancy: A Meta-analysis[J].2017,66(2).
[81]Vauthey,J.-N.,Curley,S.A.,Mahvash,A.,etc.Analysis of the efficacy of portal vein embolization for patients with extensive liver malignancy and very low future liver remnant volume, including a comparison with the associating liver partition with portal vein ligation for staged hepatectomy approa[J].2013,217(1).
[82]Jae Uk Chong,Gi Hong Choi,Dai Hoon Han,etc.Downstaging with Localized Concurrent Chemoradiotherapy Can Identify Optimal Surgical Candidates in Hepatocellular Carcinoma with Portal Vein Tumor Thrombus[J].2018,25(11).
[83]Smith, Travis J.,Manske, Jacob G.,Mathiason, Michelle A.,etc.Causal Inference in Observational Studies in Surgery Reply[J].2015,262(1).
[84]Vauthey JN,Dixon E,Abdalla EK,etc.Pretreatment assessment of hepatocellular carcinoma: expert consensus statement.[J].2010,12(5).
[85]Wei, Xubiao,Jiang, Yabo,Zhang, Xiuping,etc.Neoadjuvant Three-Dimensional Conformal Radiotherapy for Resectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Randomized, Open-Label, Multicenter Controlled Study[J].2019,37(24).
[86]Sang Yun Ha,Misun Choi,Taebum Lee,etc.The Prognostic Role of Mitotic Index in Hepatocellular Carcinoma Patients after Curative Hepatectomy[J].2015,48(1).
[87]Kaseb,A.O.,Shindoh,J.,Patt,Y.Z.,etc.Modified cisplatin/interferon α-2b/doxorubicin/5-fluorouracil (PIAF) chemotherapy in patients with no hepatitis or cirrhosis is associated with improved response rate, resectability, and survival of initially unresectable hepatocellular carcinoma[J].2013,119(18).